Single infusion of zoledronate in Paget's disease of bone: A placebo-controlled, dose-ranging study

Bone

Volumn 24, Issue 5 SUPPL., 1999, Pages 81S-85S

  Buckler, H ^a   Fraser, W ^b   Hosking, D ^c   Ryan, W ^d   Maricic, M J ^e   Singer, F ^f   Davie, M ^g   Fogelman, I ^h   Birbara, C A ⁱ   Moses, A M ^j   Lyles, K ^k   Selby, P ^l   Richardson, P ^m   Seaman, J ^m   Zelenakas, K ^m   Siris, E ⁿ  

^a HOPE HOSPITAL   (United Kingdom)

^b ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^c NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^d RUSH UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF ARIZONA   (United States)

^f JOHN WAYNE CANCER INSTITUTE   (United States)

^g ROBERT JONES AND AGNES HUNT ORTHOPAEDIC HOSPITAL   (United Kingdom)

^h GUY S HOSPITAL   (United Kingdom)

ⁱ UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^j SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^k DUKE UNIVERSITY MEDICAL CENTER   (United States)

^l UNIVERSITY OF MANCHESTER   (United Kingdom)

^m NOVARTIS PHARMA AG   (Switzerland)

ⁿ Columbia Univ Coll Phys Surgs ^*  (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; CALCIUM; CREATININE; DEOXYPYRIDINOLINE; PLACEBO; PYRIDINOLINE; ZOLEDRONIC ACID;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTHRALGIA; ARTICLE; BACKACHE; BONE PAIN; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FATIGUE; FEMALE; FEVER; HUMAN; HYDROXYPROLINE URINE LEVEL; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OSTEOCLAST; PAGET BONE DISEASE; RANDOMIZED CONTROLLED TRIAL; X RAY;

EID: 18844467280     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S8756-3282(99)00071-X     Document Type: Article

References (17)

1. Adami S., Bhalla A.K., Dorizzi R., Montesanti F., Rosini S., Salvagno G., Lo Cascio V. The acute phase response after bisphosphonate administration. Calcif Tissue Int. 41:1987;326-331.
2. Adami S., Mian M., Gatti P., Rossini M., Zamberlan N., Bertoldo F., Lo Cascio V. Effects of two oral doses of alendronate in the treatment of Paget's disease of bone. Bone. 15:1994;415-417.
3. Adami S., Salvagno G., Guarrera G., Montesanti F., Garavelli S., Rosini S., Lo Cascio V. Treatment of Paget's disease of bone with intravenous 4-amino-1-hydroxybutylidene-1,1-bisphosphonate. Calcif Tissue Int. 39:1986;226-229.
4. Bombassei G.I., Yocon O.M., Raisz L.G. Effects of intravenous pamidronate therapy on Paget's disease of bone. J Med Sci. 308:1994;226-233.
5. Bone H.G., Kleerekoper M. Clinical review 39 Paget's disease of bone . J Clin Endocrinol Metabol. 75:1992;1179-1182.
6. Burckhardt P., Thiebaud D. Treatment of Paget's disease with short courses of bisphosphonates. Singer F.R., Wallach S. Paget's disease of bone. 1991;1179-1182 Elsevier, New York.
7. Cantrill J.A., Anderson D.C. Treatment of Paget's disease of bone. Clin Endocrinol. 32:1990;507-518.
8. Delmas P.D., Chapuy M.C., Vignon E., Charon S., Briançon E., Alexandre C., Edourd C., Meunier P.J. Long-term effects of dichloromethylene diphosphonate in Paget's disease of bone. J Clin Endocrinol Metabol. 54:1982;837-844.
9. Gray R.E.S., Yates A.J.P., Preston C.J., Smith R., Russell R.G.G., Kanis J.A. Duration of effect of oral diphosphonate therapy in Paget's disease of bone. Q J Med. 64:1987;755-767.
10. Green J.R., Müller K., Jaeggi K.A. Preclinical pharmacology of CGP 42,446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res. 9:1994;745-751.
11. Kanis J.A. Pathophysiology and Treatment of Paget's Disease of Bone. 1991;Martin Dunitz, London.
12. Kelepouris, N., Siris, E., Jacobs, T., Altman, R., Ryan, W., Chausmer, A., Shai, F., Lang, R., Whyte, M., Schaffer, V., Heffernan, M., and Zelenakas, K. Comparison of three doses of intravenous pamidronate in the treatment of Paget's disease of bone. Unpublished data.
13. O'Doherty D.P., McCloskey E.V., Vasikaran S., Khan S., Kanis J.A. The effects of intravenous alendronate in Paget's disease of bone. J Bone Miner Res. 10:1995;1094-1100.
14. Preston C.J., Yates A.J.P., Beneton M.N.C., Russell R.G.G., Gray R.E.S., Smith R., Kanis J.A.K. Effective short term treatment of Paget's disease with oral etidronate. Br Med J. 292:1986;79-80.
15. Sietsema W.K., Ebetino F.H. Bisphosphonates in development for metabolic bone disease. Exp Opin Invest Drugs. 3:1994;1255-1276.
16. Siris E.S. Extensive personal experience Paget's disease of bone . J Clin Endocrinol Metabol. 80:1995;335-338.
17. Rodan G.A., Balena R. Bisphosphonates in the treatment of metabolic bone diseases. Ann Med. 25:1993;373-378.